Publications by authors named "Coty Tatum"

Article Synopsis
  • HIV and malaria often occur together in the same regions, leading to co-infection that worsens the symptoms of both diseases, but the mechanisms behind this increase in severity are not well understood.
  • A pilot study in rhesus macaques treated with antiretroviral therapy (ART) aimed to explore the effects of co-infection, revealing persistent viral loads and decreased CD4+ T-cells despite treatment, along with signs of anemia and parasitemia.
  • The study also found that co-infection increased inflammatory markers and altered neutrophil behavior, suggesting that inflammation and gastrointestinal dysfunction could play key roles in the aggravated disease pathology seen in HIV and malaria co-infection.
View Article and Find Full Text PDF

Simian immunodeficiency virus (SIV)-infected African nonhuman primates do not progress to AIDS in spite of high and persistent viral loads (VLs). Some authors consider the high viral replication observed in chronic natural SIV infections to be due to lower anti-SIV antibody titers than those in rhesus macaques, suggesting a role of antibodies in controlling viral replication. We therefore investigated the impact of antibody responses on the outcome of acute and chronic SIVagm replication in African green monkeys (AGMs).

View Article and Find Full Text PDF

Simian immunodeficiency virus SIVrcm, which naturally infects red-capped mangabeys (RCMs), is the only SIV that uses CCR2 as its main coreceptor due to the high frequency of a CCR5 deletion in RCMs. We investigated the dynamics of SIVrcm infection to identify specific pathogenic mechanisms associated with this major difference in SIV biology. Four pigtailed macaques (PTMs) were infected with SIVrcm, and infection was monitored for over 2 years.

View Article and Find Full Text PDF

We investigated the impact of rhesus macaque (RM) B-cell depletion before inoculation with the isolate SIVsmmD215. Seven RMs were treated every 3 weeks with 50 mg/kg of an anti-CD20 antibody (rituximab) starting 7 days before inoculation for 2 (n = 4) and 5 (n = 3) months. Four control animals received no antibody.

View Article and Find Full Text PDF